IMMUNOBIOLOGICAL AGENT FOR INDUCTION OF IMMUNE RESPONSE TO FILOVIRUSES: EBOLAVIRUS AND/OR MARBURGVIRUS, METHOD OF USING IMMUNOBIOLOGICAL AGENT Russian patent published in 2021 - IPC C12N1/00 C12N15/70 C12N15/11 

FIELD: immunology; virology.

SUBSTANCE: immunobiological agent was created for inducing an immune response to human pathogenic filoviruses, including a base representing a recombinant human adenovirus of serotype 26 or serotype 5 containing an expression cassette SEQIDNO:1, or SEQIDNO:2, or SEQIDNO:3, or SEQIDNO:4, or SEQIDNO:5, or SEQIDNO:6, or SEQIDNO:7, or SEQIDNO:8. In addition, an immunobiological agent was created to induce an immune response to human pathogenic filoviruses, including a base representing a recombinant vesicular stomatitis virus containing nucleic acid corresponding to cDNA SEQIDNO:9, or SEQIDNO:10, or SEQIDNO:11, or SEQIDNO:12, or SEQIDNO:13, or SEQIDNO:14, or SEQIDNO:15, or SEQIDNO:16. A method for using an immunobiological agent was also developed, consisting in its introduction into the mammalian body in an effective amount to induce specific immunity against the Ebola virus and/ or the Marburg virus. In this case, sequential administration of any of the immunobiological agents into the mammalian body with an interval of more than 1 week or simultaneous administration of several immunobiological agents into the mammalian body is possible. The developed variants of the immunobiological agent can be administered intranasally and / or subcutaneously and / or intramuscularly.

EFFECT: invention can be used as a specific preventive agent against diseases caused by Ebola virus (EBOV), Bundibugyo virus (BDBV), Sudan virus (SUDV), Marburg virus (MARV).

10 cl, 14 tbl, 13 ex